Highlights from Lung Cancer Cocktail With Science by Stephen V Liu

The Lung Cancer Cocktail With Science 2024 conference took place on September 27th in Milan, Italy.

The annual meeting provided an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context, and understand how they affected daily practice.

Participants had the opportunity to engage with faculty members who shared their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer shared their ideas and knowledge with congress participants, aiming for mutual enrichment.

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared some insights from the conference.

Special talk session by Laura Mezquita

“Special talk session chaired by Diego Signorelli, Teresa Beninato, and Giulia Galli with an informative talk on radon and lung cancer by Laura Mezquita.”

Robust discussion of targeted therapy from two global experts

“Robust discussion of targeted therapy from two global experts – Shirish Gadgeel and Enriqueta Felip.

Joining us virtually, still with commanding presence. So many emerging options – crafting the optimal sequence of therapy is now the task at hand.”

Session on targeted therapy

“Session on targeted therapy chaired by Rita Leporati, Giuseppe Viscardi, Claudia Proto with Luis Paz-Ares discussing EGFR: FLAURA2 vs MARIPOSA – longer PFS but cost of toxicity and infusions. Many prognostic factors, need predictive ones. Ivonescimab – is this the future of IO for EGFR?”

Data on duration of immunotherapy in NSCLC

“Helena Linardou presents the data on duration of immunotherapy in NSCLC. Notes different durations of therapy approved and reimbursed globally. Paucity of data – hoping we can personalize therapy with pharmacodynamic biomarkers.”

Managing early stage driver-positive NSCLC

“Jordi Remon discusses managing early stage driver-positive NSCLC. Osimertinib and alectinib with profound benefit but unanswered questions include role of chemotherapy, duration, MRD and biomarkers.”

For more posts like this, visit oncodaily.com